Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
IL268626B2 - Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient - Google Patents
[go: Go Back, main page]

IL268626B2 - Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient - Google Patents

Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient

Info

Publication number
IL268626B2
IL268626B2 IL268626A IL26862619A IL268626B2 IL 268626 B2 IL268626 B2 IL 268626B2 IL 268626 A IL268626 A IL 268626A IL 26862619 A IL26862619 A IL 26862619A IL 268626 B2 IL268626 B2 IL 268626B2
Authority
IL
Israel
Prior art keywords
inactivated
lysate
equal parts
salmonella
beta
Prior art date
Application number
IL268626A
Other languages
Hebrew (he)
Other versions
IL268626A (en
IL268626B1 (en
Inventor
Alexandre Eduardo Nowill
Original Assignee
Alexandre Eduardo Nowill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,329 external-priority patent/US10213504B2/en
Application filed by Alexandre Eduardo Nowill filed Critical Alexandre Eduardo Nowill
Publication of IL268626A publication Critical patent/IL268626A/en
Publication of IL268626B1 publication Critical patent/IL268626B1/en
Publication of IL268626B2 publication Critical patent/IL268626B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

1./ 1 CLAIMS 1. A synergistic pharmaceutical product comprising one or more antibiotics and: (a) i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii. 6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; xii. 7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); 268626/ 1 v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water.
2. The synergistic pharmaceutical product of claim 1 wherein the antibiotics are selected from the following classes: Amino Acid Derivatives, Aminoglycosides, Aureolic Acids, Aziridines, Ansamycins, Benzenoids, Benzimidazoles, Carbapenems, Cephalosporin, Coumarin-glycosides, Diphenyl Ether Derivatives, Epipolythiodioxopiperazines, Fatty Acid Derivatives, Glucosamine, Glycopeptides, Imidazoles, Indol Derivatives, Lipopeptides Macrolactams, Macrolides, Nucleosides. Penicillins and Cephalosporins (beta-Lactams), Peptides, Peptidyl Nucleosides, Phenicoles, Polyenes, Polyethers, Pyridines and Pyrimidines, Quinolones and Fluoroquinolones, Statins, Steroids, Sulfonamides, Taxoides and Tetracyclines.
3. The synergistic pharmaceutical product of claim 2 wherein the antibiotics are selected from the following classes: ansamycins, Penicillins, Cephalosporins, Carbapenems and Lipopeptides.
4. A synergistic effective amount of one or more antibiotics and (a) 268626/ 1 i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii. 6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; xii. 7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; 268626/ 1 vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water, for use in a method to treat sepsis and multi resistant bacterial infection in a human or an animal.
5. A synergistic effective amount of a composition comprising (a) i. 0,0036 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0,0036 µg/mL PPD; iii.
6.31 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.31 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.404 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.101 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.31 µg/mL Oidiomycin (antigenic extract of Candida albicans); viii. 6.31 µg/mL Trichophytin (antigenic extract of Tricophyton sp); ix. 6.31 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.31 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 20 µg/mL Attenuated yellow fever virus strain 17 D204; 268626/ 1 xii.
7.5 mg/mL Sodium Chloride; xiii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiv. 0.06 mg/mL Potassium phosphate monobasic; xv. 2.5 mg/mL Phenol; and xvi. water; or (b) i. 0.004 ng/mL Koch’s Turberculin (inactivated Mycobacterium bovis lysate); ii. 0.004 g/mL PPD; iii. 6.94 µg/mL Inactivated Staphylococcus lysate (Staphylococcus aureus and Staphylococcus epidermidis in equal parts); iv. 6.94 µg/ml Inactivated Steptococcus lysate (Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus faecalis in equal parts); v. 0.444 µg/mL Streptokinase derived from inactivated beta-hemolytic Streptococcus lysate purification; vi. 0.111 µg/mL Dornase derived from inactivated beta-hemolytic Streptococcus lysate purification; vii. 6.94 µg/mL Inactivated Candida lysate (Candida albicans and Candida glabrata in equal parts); viii. 6.94 µg/mL Inactivated dermatophytes lysate (Epidermophytonfloccosum, Microsporum cannis, Trichophyton mentagrophytes of the interdigitale variety in equal parts); ix. 6.94 µg/mL Inactivated enteropathogenic Escherichia coli lysate (EPEC); x. 6.94 µg/mL Inactivated Salmonella lysate (Salmonella bongori, Salmonella enterica and Salmonella subterranea in equal parts); xi. 7.5 mg/mL Sodium Chloride; xii. 0.48 mg/mL Sodium phosphate dibasic heptahydrate; xiii. 0.06 mg/mL Potassium phosphate monobasic; xiv. 2.5 mg/mL Phenol; and xv. water, for use in a method to modulate an immune system response in a human or an animal who has a bacterial infection. For the Applicant Paulina Ben-Ami Patent Attorneys
IL268626A 2017-02-13 2018-02-15 Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient IL268626B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/431,329 US10213504B2 (en) 2011-03-18 2017-02-13 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
PCT/BR2018/000004 WO2018145180A1 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Publications (3)

Publication Number Publication Date
IL268626A IL268626A (en) 2019-10-31
IL268626B1 IL268626B1 (en) 2023-12-01
IL268626B2 true IL268626B2 (en) 2024-04-01

Family

ID=63106848

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268626A IL268626B2 (en) 2017-02-13 2018-02-15 Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient

Country Status (11)

Country Link
EP (1) EP3579868A4 (en)
JP (1) JP2020507629A (en)
KR (1) KR20190139209A (en)
CN (1) CN110709099B (en)
AU (1) AU2018217441B2 (en)
BR (1) BR112019016670A2 (en)
IL (1) IL268626B2 (en)
MX (1) MX2019009689A (en)
NZ (1) NZ757251A (en)
RU (1) RU2019128674A (en)
WO (1) WO2018145180A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102857635B1 (en) 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 Method for designing highly immunogenic mimotope and device using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230228A1 (en) * 2003-04-30 2004-11-23 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
CA2555253A1 (en) * 2004-02-06 2005-08-25 Yale University Compositions of pamps and listeria monocytogenes and methods of use
EP2586790A3 (en) * 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMORAL AND CELLULAR IMMUNITY BY MEANS OF COMBINATORY ACTIVATION OF GREAT LIKE RECEPTORS
US10988511B2 (en) * 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
AU2010272243A1 (en) * 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Also Published As

Publication number Publication date
CN110709099B (en) 2024-03-29
NZ757251A (en) 2026-03-27
EP3579868A4 (en) 2021-01-06
WO2018145180A1 (en) 2018-08-16
RU2019128674A3 (en) 2021-06-18
RU2019128674A (en) 2021-03-16
CN110709099A (en) 2020-01-17
JP2020507629A (en) 2020-03-12
EP3579868A1 (en) 2019-12-18
BR112019016670A2 (en) 2020-04-14
IL268626A (en) 2019-10-31
AU2018217441A1 (en) 2019-10-03
KR20190139209A (en) 2019-12-17
IL268626B1 (en) 2023-12-01
MX2019009689A (en) 2019-12-18
AU2018217441B2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
Zalewska-Piątek et al. Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains-Review
Jeon et al. Underlying mechanism of antimicrobial activity of chitosan microparticles and implications for the treatment of infectious diseases
EP4623922A3 (en) Altering microbial populations & modifying microbiota
US9140698B2 (en) Modulating bacterial MAM polypeptides in pathogenic disease
JP2014042533A5 (en)
BR112019011660A2 (en) bacteriophage compositions comprising respiratory antibacterial phages and methods of using them
JP6204930B2 (en) Protection against Staphylococcus aureus infections with multivalent vaccines
IL268626B1 (en) Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient
Mosquito et al. Effect of bovine lactoferrin in Salmonella ser. Typhimurium infection in mice
BR112021021443A2 (en) Protein or antigenic fragment thereof, composition, expression vector, plurality of cells, method, and article of manufacture
Huy et al. Intracellular trafficking modulation by ginsenoside Rg3 inhibits Brucella abortus uptake and intracellular survival within RAW 264.7 cells
Yang et al. Inhibition of bacterial swimming by heparin binding of flagellin FliC from Escherichia coli strain Nissle 1917
Tonnaer et al. Advances in understanding the pathogenesis of pneumococcal otitis media
Li et al. Complete genome sequence of Salmonella enterica serovar Pullorum multidrug resistance strain S06004 from China
Gulbe et al. In Vitro Assessment for Antimicrobial Activity of Lactobacillus Helveticus and its Natural Glycopeptides Against Mastitis Causing Pathogens in Dairy Cat
WO2018035046A1 (en) Treating infections using idsd from proteus mirabilis
EP1774975A1 (en) Use of human lysozyme in preparation of medicine for treating acne
BR112021006339A2 (en) immunoproteasome inhibitor formulation
Likaa et al. Immunostimulatory, Antibacterial and antibiofilm activity of purified Donkey colostrums lactoferrin on multidrug resistance Serratia liquefaciens producing Intl gene
Naderer Towards re-purposing BH3-mimetics in Legionella and viral infections
Maya et al. Antimicrobial peptides past, present and future
JP2023087090A (en) Salmonella vaccine using SseJ protein
WO2021151450A1 (en) Targeted drug delivery system using bacterial ghosts of salmonella toward hepatic cancer cells
ژاله خنیفر et al. Comparison of immunization potential from recombinant proteins EIT and Stx2B nanoparticulated based on chitosan in animal model, as nanovaccin candidate against E. coli O157: H7
Banks Molecular investigation of Bdellovibrio bacteriovorus envelope processes associated with bacterial predation